First Time Loading...
A

Apeloa Pharmaceutical Co Ltd
SZSE:000739

Watchlist Manager
Apeloa Pharmaceutical Co Ltd
SZSE:000739
Watchlist
Price: 14.75 CNY -1.67% Market Closed
Updated: May 29, 2024

Apeloa Pharmaceutical Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Apeloa Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison

Comparables:
C
1093
H
3692
600436
600276
000538

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Apeloa Pharmaceutical Co Ltd
SZSE:000739
Cash from Operating Activities
¥1B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Cash from Operating Activities
¥4.2B
CAGR 3-Years
-15%
CAGR 5-Years
2%
CAGR 10-Years
21%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
¥3.1B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Operating Activities
¥2.1B
CAGR 3-Years
5%
CAGR 5-Years
19%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
¥8.7B
CAGR 3-Years
61%
CAGR 5-Years
26%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
¥3.3B
CAGR 3-Years
1%
CAGR 5-Years
30%
CAGR 10-Years
12%

See Also

What is Apeloa Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1B CNY

Based on the financial report for Dec 31, 2023, Apeloa Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 1B CNY.

What is Apeloa Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
4%

Over the last year, the Cash from Operating Activities growth was -22%. The average annual Cash from Operating Activities growth rates for Apeloa Pharmaceutical Co Ltd have been -1% over the past three years , 4% over the past five years .